Almac Completes Its Expansion Plan to Pharma Services Facilities
Almac’s Pharma Services
business unit has announced the completion of a $13.75 million expansion to the company’s existing facilities at the Group’s headquarters in Craigavon, Northern Ireland.
The completion of a three story extension to the existing commercial manufacture facility in June 2009 expanded Pharma Services’ laboratory and office areas by 30,000 ft2. The new laboratories aim to enhance the existing analytical and microbiological drug product support services.
Remodelling of the now 120,000 ft2 commercial manufacture facility was completed in March 2010. Remodeling included expansion in microbiological and sterility test areas, new yellow light labs, and office and meeting room expansion. Method development, validation, and transfer supporting multiple client projects, are offered over a wide range of technologies from our expanded facility.
Graeme McBurney, President & M.D of Almac Pharma Services commented: “Increased client demand for our integrated services has resulted in the strategic decision to make this investment and expansion, both in terms of space and the additional team members we are recruiting. I look forward to working with the current and new members of our team.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
